These separate in vivo observations support the combination of 4-1BBL and IL-15TP for improved efficacy and suggest that the RTX-240 mechanism of action includes expansion of NK cells and CD8 + T cells in the spleen and increased infiltration of activated NK cells and CD8 + T cells in the tumor site. Here, CD8A is linked to neoplasm.